POLOCAINE W Drug Patent Profile
✉ Email this page to a colleague
When do Polocaine W patents expire, and when can generic versions of Polocaine W launch?
Polocaine W is a drug marketed by Dentsply Pharm and is included in one NDA.
The generic ingredient in POLOCAINE W is levonordefrin; mepivacaine hydrochloride. There are two drug master file entries for this compound. Additional details are available on the levonordefrin; mepivacaine hydrochloride profile page.
US Patents and Regulatory Information for POLOCAINE W
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dentsply Pharm | POLOCAINE W/ LEVONORDEFRIN | levonordefrin; mepivacaine hydrochloride | INJECTABLE;INJECTION | 089517-001 | Apr 14, 1988 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
